The primary goal in the treatment of<unk>  of<unk>  disease is to treat the underlying disease itself. Supplemental iron is recommended, as needed, to keep the transferrin saturation of above 20 percent and a serum ferritin level of above 100 ng/mL. Intravenous iron is more effective than oral supplementaion. Stable patients can be administered synthetically prepared erythropoiesis-stimulating agent such as erythropoietin or darbepoietin. It is important to give oral iron supplementation to all the patients receiving erythropoietin or darbepoetin, in order to maintain a transferrin saturation more than 20 percent and a serum ferritin more than 100 ng/mL. In case of severe disease, blood transfusion is recommended. If the case is underlying malignancy, chemotherapy or radiotherapy may transiently exacerbate<unk>  due to myelosuppressive effects, but in the long term, it leads to improvement. If the cause is inflammatory disorder, such as rheumatoid arthritis the management of the disease with a disease-modifying antirheumatic drug (DMARD) improves the<unk>  significantly.
Anemia of chronic disease medical therapy
Anemia of chronic disease surgery
Hemolytic anemia laboratory findings
Myelofibrosis risk factors
Anemia of chronic disease laboratory findings
Sideroblastic anemia laboratory findings
Heparin-induced thrombocytopenia medical therapy
Thrombotic thrombocytopenic purpura risk factors